21 results on '"Pickering, Matthew C"'
Search Results
2. Canonical and noncanonical functions of complement in systemic lupus erythematosus.
- Author
-
Pickering, Matthew C and Botto, Marina
- Subjects
SYSTEMIC lupus erythematosus ,COMPLEMENT activation ,SOFT tissue injuries - Abstract
For many years complement activation in systemic lupus erythematosus (SLE) was viewed as a major cause of tissue injury. However, human and murine studies showed that complement plays a protective as well as a proinflammatory role in tissue damage. A hierarchy is apparent with early classical pathway components, particularly C1q, exerting the greatest influence. Understanding the mechanisms underlying the protective function(s) of complement remains an important challenge for the future and has implications for the use of complement therapy in SLE. We review recent advances in the field and give a new perspective on the complement conundrum in SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Factor H–Related Protein 1 Drives Disease Susceptibility and Prognosis in C3 Glomerulopathy
- Author
-
Márquez-Tirado, Bárbara, Gutiérrez-Tenorio, Josué, Tortajada, Agustín, Lucientes Continente, Laura, Caravaca-Fontán, Fernando, Malik, Talat H., Roldán Montero, Raquel, Elías, Sandra, Saiz Gonzalez, Ana, Fernández-Juarez, Gema, Sánchez-Corral, Pilar, Pickering, Matthew C., Praga, Manuel, Rodríguez de Córdoba, Santiago, Goicoechea de Jorge, Elena, Ministerio de Ciencia e Innovación (España), European Commission, Comunidad de Madrid, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Gutiérrez-Tenorio, Josué [0000-0001-8590-5455], Tortajada, Agustín [0000-0002-2131-2594], Lucientes, Laura [0000-0001-5596-370X], Caravaca-Fontán, Fernando [0000-0002-5830-9663], Saiz Gonzalez, Ana [0000-0001-7110-450X], Fernández-Juárez, Gema [0000-0001-6641-7763], Sánchez-Corral, Pilar [0000-0003-4212-1233], Pickering, Matthew C. [0000-0002-1153-0192], Praga, Manuel [0000-0001-9270-1071], Rodríguez de Córdoba, Santiago [0000-0001-6401-1874], Goicoechea de Jorge, Elena [0000-0002-4978-2483], Gutiérrez-Tenorio, Josué, Tortajada, Agustín, Lucientes, Laura, Caravaca-Fontán, Fernando, Saiz Gonzalez, Ana, Fernández-Juárez, Gema, Sánchez-Corral, Pilar, Pickering, Matthew C., Praga, Manuel, Rodríguez de Córdoba, Santiago, and Goicoechea de Jorge, Elena
- Subjects
Glomerular disease ,Disease susceptibility ,DNA Copy Number Variations ,Factor H-related protein 1 ,Complement ,Genetic renal disease ,Glomerulonephritis, IGA ,General Medicine ,Blood Proteins ,Complement C3 ,Prognosis ,Basic Research ,Nephrology ,Complement Factor H ,Complement C3b Inactivator Proteins ,Humans ,C3 glomerulopathy ,Disease Susceptibility - Abstract
17 p.-8 fig., Background: C3 glomerulopathy (C3G) is a heterogeneous group of chronic renal diseases characterized predominantly by glomerular C3 deposition and complement dysregulation. Mutations in factor H-related (FHR) proteins resulting in duplicated dimerization domains are prototypical of C3G, although the underlying pathogenic mechanism is unclear., Methods: Using in vitro and in vivo assays, we performed extensive characterization of an FHR-1 mutant with a duplicated dimerization domain. To assess the FHR-1 mutant's association with disease susceptibility and renal prognosis, we also analyzed CFHR1 copy number variations and FHR-1 plasma levels in two Spanish C3G cohorts and in a control population., Results: Duplication of the dimerization domain conferred FHR-1 with an increased capacity to interact with C3-opsonized surfaces, which resulted in an excessive activation of the alternative pathway. This activation does not involve C3b binding competition with factor H. These findings support a scenario in which mutant FHR-1 binds to C3-activated fragments and recruits native C3 and C3b; this leads to formation of alternative pathway C3 convertases, which increases deposition of C3b molecules, overcoming FH regulation. This suggests that a balanced FHR-1/FH ratio is crucial to control complement amplification on opsonized surfaces. Consistent with this conceptual framework, we show that the genetic deficiency of FHR-1 or decreased FHR-1 in plasma confers protection against developing C3G and associates with better renal outcome., Conclusions: Our findings explain how FHR-1 mutants with duplicated dimerization domains result in predisposition to C3G. They also provide a pathogenic mechanism that may be shared by other diseases, such as IgA nephropathy or age-related macular degeneration, and identify FHR-1 as a potential novel therapeutic target in C3G., E. Goicoechea de Jorge is supported by Ministerio de Ciencia e Innovación grant RTI2018-095955-B-100 and the European Union’s Horizon 2020 Framework Programme grant 899163. J. Gutiérrez-Tenorio is supported by Ministerio de Ciencia e Innovación grant BES-2015-073833. L. Lucientes Continente is supported by the Autonomous Region of Madrid grant S2017/BMD-3673. G. Fernández-Juarez, P. Sánchez-Corral, B. Márquez-Tirado, and M. Praga are supported by the Instituto de Salud Carlos III and the European Union’s European Regional Development Fund grants PI19/01695, PI19/00970, and PI19/01624, respectively. M.C. Pickering is a Wellcome Trust Senior Fellow in Clinical Science (212252/Z/18/Z). S. Rodríguez de Córdoba is supported by the Ministerio de Economía y Competitividad grant PID2019-104912RB-100 and Autonomous Region of Madrid grant S2017/BMD-3673.
- Published
- 2022
4. Homodimeric Minimal Factor H: In Vivo Tracking and Extended Dosing Studies in Factor H Deficient Mice.
- Author
-
Kamala, Ola, Malik, Talat H., Hallam, Thomas M., Cox, Thomas E., Yang, Yi, Vyas, Falguni, Luli, Saimir, Connelly, Chloe, Gibson, Beth, Smith-Jackson, Kate, Denton, Harriet, Pappworth, Isabel Y., Huang, Lei, Kavanagh, David, Pickering, Matthew C., and Marchbank, Kevin J.
- Subjects
MICE ,ANTIBODY formation ,GENE therapy ,LABORATORY mice ,THERAPEUTICS - Abstract
C3 glomerulopathy (C3G) is associated with dysregulation of the alternative pathway (AP) of complement and treatment options remain inadequate. Factor H (FH) is a potent regulator of the AP. An in-depth analysis of FH-related protein dimerised minimal (mini)-FH constructs has recently been published. This analysis showed that addition of a dimerisation module to mini-FH not only increased serum half-life but also improved complement regulatory function, thus providing a potential treatment option for C3G. Herein, we describe the production of a murine version of homodimeric mini-FH [mHDM-FH (mFH
1–5^18–20^R1–2 )], developed to reduce the risk of anti-drug antibody formation during long-term experiments in murine models of C3G and other complement-driven pathologies. Our analysis of mHDM-FH indicates that it binds with higher affinity and avidity to WT mC3b when compared to mouse (m)FH (mHDM-FH KD =505 nM; mFH KD =1370 nM) analogous to what we observed with the respective human proteins. The improved binding avidity resulted in enhanced complement regulatory function in haemolytic assays. Extended interval dosing studies in CFH-/- mice (5mg/kg every 72hrs) were partially effective and bio-distribution analysis in CFH-/- mice, through in vivo imaging technologies, demonstrates that mHDM-FH is preferentially deposited and remains fixed in the kidneys (and liver) for up to 4 days. Extended dosing using an AAV- human HDM-FH (hHDM-FH) construct achieved complete normalisation of C3 levels in CFH-/- mice for 3 months and was associated with a significant reduction in glomerular C3 staining. Our data demonstrate the ability of gene therapy delivery of mini-FH constructs to enhance complement regulation in vivo and support the application of this approach as a novel treatment strategy in diseases such as C3G. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
5. Plasma Lectin Pathway Complement Proteins in Patients With COVID-19 and Renal Disease.
- Author
-
Medjeral-Thomas, Nicholas R., Troldborg, Anne, Hansen, Annette G., Gisby, Jack, Clarke, Candice L., Prendecki, Maria, McAdoo, Stephen P., Sandhu, Eleanor, Lightstone, Liz, Thomas, David C., Willicombe, Michelle, Botto, Marina, Peters, James E., Pickering, Matthew C., and Thiel, Steffen
- Subjects
COVID-19 ,LECTINS ,COVID-19 pandemic ,KIDNEY diseases ,CHRONIC kidney failure ,BLOOD proteins - Abstract
We do not understand why non-white ethnicity and chronic kidney disease increase susceptibility to COVID-19. The lectin pathway of complement activation is a key contributor to innate immunity and inflammation. Concentrations of plasma lectin pathway proteins influence pathway activity and vary with ethnicity. We measured circulating lectin proteins in a multi-ethnic cohort of chronic kidney disease patients with and without COVID19 infection to determine if lectin pathway activation was contributing to COVID19 severity. We measured 11 lectin proteins in serial samples from a cohort of 33 patients with chronic kidney impairment and COVID19. Controls were single plasma samples from 32 patients on dialysis and 32 healthy individuals. We demonstrated multiple associations between recognition molecules and associated proteases of the lectin pathway and COVID-19, including COVID-19 severity. Some of these associations were unique to patients of Asian and White ethnicity. Our novel findings demonstrate that COVID19 infection alters the concentration of plasma lectin proteins and some of these changes were linked to ethnicity. This suggests a role for the lectin pathway in the host response to COVID-19 and suggest that variability within this pathway may contribute to ethnicity-associated differences in susceptibility to severe COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Gain-of-function factor H-related 5 protein impairs glomerular complement regulation resulting in kidney damage.
- Author
-
Malik, Talat H., Gitterman, Daniel P., Lavin, Deborah P., Lomax-Browne, Hannah J., Hiemeyer, E. Christina, Moran, Linda B., Boroviak, Katharina, Cook, H. Terence, Gilmore, Alyssa C., Mandwie, Mawj, Ahmad, Amina, Alexander, Ian E., Logan, Grant J., Marchbank, Kevin J., Bradley, Allan, and Pickering, Matthew C.
- Subjects
MUTANT proteins ,CHRONIC kidney failure ,KIDNEYS ,ADENO-associated virus ,GENES ,COMMERCIAL products - Abstract
Genetic variation within the factor H-related (FHR) genes is associated with the complement-mediated kidney disease, C3 glomerulopathy (C3G). There is no definitive treatment for C3G, and a significant proportion of patients develop end-stage renal disease. The prototypical example is CFHR5 nephropathy, through which an internal duplication within a single CFHR5 gene generates a mutant FHR5 protein (FHR5mut) that leads to accumulation of complement C3 within glomeruli. To elucidate how abnormal FHR proteins cause C3G, we modeled CFHR5 nephropathy in mice. Animals lacking the murine factor H (FH) and FHR proteins, but coexpressing human FH and FHR5mut (hFH-FHR5mut), developed glomerular C3 deposition, whereas mice coexpressing human FH with the normal FHR5 protein (hFH-FHR5) did not. Like in patients, the FHR5mut had a dominant gain-of-function effect, and when administered in hFH-FHR5 mice, it triggered C3 deposition. Importantly, adeno-associated virus vector-delivered homodimeric mini- FH, a molecule with superior surface C3 binding compared to FH, reduced glomerular C3 deposition in the presence of the FHR5mut. Our data demonstrate that FHR5mut causes C3G by disrupting the homeostatic regulation of complement within the kidney and is directly pathogenic in C3G. These results support the use of FHderived molecules with enhanced C3 binding for treating C3G associated with abnormal FHR proteins. They also suggest that targeting FHR5 represents a way to treat complement-mediated kidney injury. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression.
- Author
-
Prendecki, Maria, Clarke, Candice, Medjeral-Thomas, Nicholas, McAdoo, Stephen P, Sandhu, Eleanor, Peters, James E, Thomas, David C, Willicombe, Michelle, Botto, Marina, and Pickering, Matthew C
- Subjects
COVID-19 ,HEMODIALYSIS patients ,COMPLEMENT activation ,DISEASE progression ,ENZYME-linked immunosorbent assay - Abstract
Background Complement activation may play a pathogenic role in patients with severe coronavirus disease 2019 (COVID-19) by contributing to tissue inflammation and microvascular thrombosis. Methods Serial samples were collected from patients receiving maintenance haemodialysis (HD). Thirty-nine patients had confirmed COVID-19 and 10 patients had no evidence of COVID-19. Plasma C5a and C3a levels were measured using enzyme-linked immunosorbent assay. Results We identified elevated levels of plasma C3a and C5a in HD patients with severe COVID-19 compared with controls. Serial sampling identified that C5a levels were elevated prior to clinical deterioration in patients who developed severe disease. C3a more closely mirrored both clinical and biochemical disease severity. Conclusions Our findings suggest that activation of complement plays a role in the pathogenesis of COVID-19, leading to endothelial injury and lung damage. C5a may be an earlier biomarker of disease severity than conventional parameters such as C-reactive protein and this warrants further investigation in dedicated biomarker studies. Our data support the testing of complement inhibition as a therapeutic strategy for patients with severe COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Complement Factor H Modulates Splenic B Cell Development and Limits Autoantibody Production.
- Author
-
Kiss, Máté G., Ozsvár-Kozma, Mária, Porsch, Florentina, Göderle, Laura, Papac-Miličević, Nikolina, Bartolini-Gritti, Barbara, Tsiantoulas, Dimitrios, Pickering, Matthew C., and Binder, Christoph J.
- Subjects
COMPLEMENT factor H ,B cells ,B cell receptors ,COMPLEMENT receptors ,HUMORAL immunity ,DESMOGLEINS ,ECULIZUMAB - Abstract
Complement factor H (CFH) has a pivotal role in regulating alternative complement activation through its ability to inhibit the cleavage of the central complement component C3, which links innate and humoral immunity. However, insights into the role of CFH in B cell biology are limited. Here, we demonstrate that deficiency of CFH in mice leads to altered splenic B cell development characterized by the accumulation of marginal zone (MZ) B cells. Furthermore, B cells in Cf h
−/− mice exhibit enhanced B cell receptor (BCR) signaling as evaluated by increased levels of phosphorylated Bruton's tyrosine kinase (pBTK) and phosphorylated spleen tyrosine kinase (pSYK). We show that enhanced BCR activation is associated with uncontrolled C3 consumption in the spleen and elevated complement receptor 2 (CR2, also known as CD21) levels on the surface of mature splenic B cells. Moreover, aged Cf h−/− mice developed splenomegaly with distorted spleen architecture and spontaneous B cell-dependent autoimmunity characterized by germinal center hyperactivity and a marked increase in anti-double stranded DNA (dsDNA) antibodies. Taken together, our data indicate that CFH, through its function as a complement repressor, acts as a negative regulator of BCR signaling and limits autoimmunity. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
9. Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM.
- Author
-
Goetz, Lindsey, Laskowski, Jennifer, Renner, Brandon, Pickering, Matthew C., Kulik, Liudmila, Klawitter, Jelena, Stites, Erik, Christians, Uwe, van der Vlag, Johan, Ravichandran, Kameswaran, Holers, V. Michael, and Thurman, Joshua M.
- Abstract
Abstract: Natural IgM binds to glomerular epitopes in several progressive kidney diseases. Previous work has shown that IgM also binds within the glomerulus after ischemia/reperfusion (I/R) but does not fully activate the complement system. Factor H is a circulating complement regulatory protein, and congenital or acquired deficiency of factor H is a strong risk factor for several types of kidney disease. We hypothesized that factor H controls complement activation by IgM in the kidney after I/R, and that heterozygous factor H deficiency would permit IgM‐mediated complement activation and injury at this location. We found that mice with targeted heterozygous deletion of the gene for factor H developed more severe kidney injury after I/R than wild‐type controls, as expected, but that complement activation within the glomeruli remained well controlled. Furthermore, mice that are unable to generate soluble IgM were not protected from renal I/R, even in the setting of heterozygous factor H deficiency. These results demonstrate that factor H is important for limiting injury in the kidney after I/R, but it is not critical for controlling complement activation by immunoglobulin within the glomerulus in this setting. IgM binds to glomerular epitopes after I/R, but it is not a significant source of injury. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Update on C3 glomerulopathy.
- Author
-
Barbour, Thomas D., Ruseva, Marieta M., and Pickering, Matthew C.
- Subjects
KIDNEY glomerulus diseases ,COMPLEMENT activation ,BASAL lamina ,COMPLEMENT factor H ,NEPHROLOGY ,MEDICAL research - Abstract
C3 glomerulopathy refers to a disease process in which abnormal control of complement activation, degradation or deposition results in predominant C3 fragment deposition within the glomerulus and glomerular damage. Recent studies have improved our understanding of its pathogenesis. The key abnormality is uncontrolled C3b amplification in the circulation and/or along the glomerular basement membrane. Family studies in which disease segregates with structurally abnormal complement factor H-related (CFHR) proteins demonstrate that abnormal CFHR proteins are important in some types of C3 glomerulopathy. This is currently thought to be due to the ability of these proteins to antagonize the major negative regulator of C3 activation, complement factor H (CFH), a process termed 'CFH de-regulation'. Recent clinicopathological cohort studies have led to further refinements in case definition, culminating in a 2013 consensus report, which provides recommendations regarding investigation and treatment. Early clinical experience with complement-targeted therapeutics, notably C5 inhibitors, has also now been published. Here, we summarize the latest developments in C3 glomerulopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Dense Deposit Disease and C3 Glomerulopathy.
- Author
-
Barbour, Thomas D., Pickering, Matthew C., and Terence Cook, H.
- Abstract
Summary: C3 glomerulopathy refers to those renal lesions characterized histologically by predominant C3 accumulation within the glomerulus, and pathogenetically by aberrant regulation of the alternative pathway of complement. Dense deposit disease is distinguished from other forms of C3 glomerulopathy by its characteristic appearance on electron microscopy. The extent to which dense deposit disease also differs from other forms of C3 glomerulopathy in terms of clinical features, natural history, and outcomes of treatment including renal transplantation is less clear. We discuss the pathophysiology of C3 glomerulopathy, with evidence for alternative pathway dysregulation obtained from affected individuals and complement factor H (Cfh)-deficient animal models. Recent linkage studies in familial C3 glomerulopathy have shown genomic rearrangements in the Cfh-related genes, for which the novel pathophysiologic concept of Cfh deregulation has been proposed. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
12. Recent insights into C3 glomerulopathy.
- Author
-
Barbour, Thomas D., Pickering, Matthew C., and Cook, H. Terence
- Subjects
- *
GLOMERULONEPHRITIS , *HISTOLOGY , *ETIOLOGY of diseases , *KIDNEY disease treatments , *AUTOANTIBODIES , *ECULIZUMAB , *MOLECULAR biology - Abstract
‘C3 glomerulopathy’ is a recent disease classification comprising several rare types of glomerulonephritis (GN), including dense deposit disease (DDD), C3 glomerulonephritis (C3GN) and CFHR5 nephropathy. These disorders share the key histological feature of isolated complement C3 deposits in the glomerulus. A common aetiology involving dysregulation of the alternative pathway (AP) of complement has been elucidated in the past decade, with genetic defects and/or autoantibodies able to be identified in a proportion of patients. We review the clinical and histological features of C3 glomerulopathy, relating these to underlying molecular mechanisms. The role of uncontrolled C3 activation in pathogenesis is emphasized, with important lessons from animal models. Methods, advantages and limitations of gene testing in the assessment of individuals or families with C3 glomerulopathy are discussed. While no therapy has yet been shown consistently effective, clinical evaluation of agents targeting specific components of the complement system is ongoing. However, limits to current knowledge regarding the natural history and the appropriate timing and duration of proposed therapies need to be addressed. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. Ultraviolet-Radiation-Induced Keratinocyte Apoptosis in C1q-Deficient Mice.
- Author
-
Pickering, Matthew C., Fischer, Susanne, Lewis, Margarita R., Walport, Mark J., Botto, Marina, and Cook, H. Terence
- Subjects
- *
ULTRAVIOLET radiation , *APOPTOSIS - Abstract
Exposure to ultraviolet B radiation is an important trigger of both systemic and cutaneous disease flares in individuals with systemic lupus erythematosus. More than 90% of individuals with homozygous C1q deficiency develop a systemic-lupus-erythematosus-like illness, which is typically associated with a severe photosensitive rash. Apoptotic, human keratinocytes have been shown in vitro to bind C1q, in the absence of antibody. These observations, together with the hypothesis that a major source of the autoantigens driving the immune response in systemic lupus erythematosus comes from apoptotic cells, led us to investigate the effects of murine C1q deficiency on ultraviolet-radiation-induced keratinocyte apoptosis in vivo. In this work, we demonstrated C1q binding to apoptotic murine keratinocytes in vitro and showed for the first time that C1q is also present on sunburn cells in vivo. In addition to C1q, we detected C3 deposition on sunburn cells in both wild-type and C1q-deficient mice, suggesting activation of the alternative pathway. Following acute ultraviolet exposure in vivo, no difference in the rate of clearance of sunburn cells was found in C1q-deficient mice from three different genetic backgrounds, compared with strain-matched wild-type controls. Furthermore, chronic ultraviolet exposure did not result in the production of autoantibodies or the development of glomerulonephritis. Our findings suggest that C1q does not play a critical role in the physiologic clearance of apoptotic murine keratinocytes in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
14. Complement factor H-deficient mice develop spontaneous hepatic tumors.
- Author
-
Laskowski, Jennifer, Renner, Brandon, Pickering, Matthew C., Serkova, Natalie J., Smith-Jones, Peter M., Clambey, Eric T., Nemenoff, Raphael A., and Thurman, Joshua M.
- Subjects
- *
COMPLEMENT factor H , *COMPLEMENT activation , *EYE diseases , *TUMORS , *HEPATOCELLULAR carcinoma - Abstract
Hepatocellular carcinoma (HCC) is difficult to detect, carries a poor prognosis, and is one of few cancers with an increasing yearly incidence. Molecular defects in complement factor H (CFH), a critical regulatory protein of the complement alternative pathway (AP), are typically associated with inflammatory diseases of the eye and kidney. Little is known regarding the role of CFH in controlling complement activation within the liver. While studying aging CFH-deficient (fH-/-) mice, we observed spontaneous hepatic tumor formation in more than 50% of aged fH-/- males. Examination of fH-/- livers (3-24 months) for evidence of complement-mediated inflammation revealed widespread deposition of complement-activation fragments throughout the sinusoids, elevated transaminase levels, increased hepatic CD8+ and F4/80+ cells, overexpression of hepatic mRNA associated with inflammatory signaling pathways, steatosis, and increased collagen deposition. Immunostaining of human HCC biopsies revealed extensive deposition of complement fragments within the tumors. Investigating the Cancer Genome Atlas also revealed that increased CFH mRNA expression is associated with improved survival in patients with HCC, whereas mutations are associated with worse survival. These results indicate that CFH is critical for controlling complement activation in the liver, and in its absence, AP activation leads to chronic inflammation and promotes hepatic carcinogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Conversion of the Liver into a Biofactory for DNaseI Using Adeno-Associated Virus Vector Gene Transfer Reduces Neutrophil Extracellular Traps in a Model of Systemic Lupus Erythematosus.
- Author
-
Ahmad, Amina, Mandwie, Mawj, O'Sullivan, Kim M., Smyth, Christine, York, Jarrod, Doyle, Helen, Holdsworth, Stephen R., Pickering, Matthew C., Lachmann, Peter J., Alexander, Ian E., and Logan, Grant J.
- Subjects
- *
ADENO-associated virus , *NEUTROPHILS , *SYSTEMIC lupus erythematosus , *GENETIC transformation , *COMPLEMENT (Immunology) , *KIDNEY physiology , *IMMUNOGLOBULIN G - Abstract
Adeno-associated virus (AAV) vectors are proving to be clinically transformative tools in the treatment of monogenic genetic disease. Rapid ongoing development of this technology promises to not only increase the number of monogenic disorders amenable to this approach but also to bring diseases with complex multigenic and nongenetic etiologies within therapeutic reach. In this study, we explore the broader paradigm of converting the liver into a biofactory for systemic output of therapeutic molecules using AAV-mediated delivery of the endonuclease DNaseI as an exemplar. DNaseI can clear neutrophil extracellular traps (NETs), which are nuclear-protein structures possessing antimicrobial action, also involved in the pathophysiology of clinically troubling immune-mediated diseases. However, a translational challenge is short half-life of the enzyme in vivo (<5 h). This study demonstrates that AAV-mediated liver-targeted gene transfer stably induces serum DNaseI activity to >190-fold above physiological levels. In lupus-prone mice (NZBWF1), the activity was maintained for longer than 6 months, the latest time point tested, and resulted in a clear functional effect with reduced renal presence of neutrophils, NETs, IgG, and complement C3. However, treatment in this complex disease model did not extend lifespan, improve serological endpoints, or preserve renal function, indicating there are elements of pathophysiology not accessible to DNaseI in the NZBWF1 model. We conclude that a translational solution to the challenge of short half-life of DNaseI is AAV-mediated gene delivery and that this may be efficacious in treating disease where NETs are a dominant pathological mechanism. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Adeno-Associated Virus Vector Gene Delivery Elevates Factor I Levels and Downregulates the Complement Alternative Pathway In Vivo.
- Author
-
Ahmad, Amina, Mandwie, Mawj, Dreismann, Anna K., Smyth, Christine M., Doyle, Helen, Malik, Talat H., Pickering, Matthew C., Lachmann, Peter J., Alexander, Ian E., and Logan, Grant J.
- Subjects
- *
ADENO-associated virus , *COMPLEMENT (Immunology) , *COMPLEMENT activation , *LABORATORY mice , *SYSTEMIC lupus erythematosus - Abstract
The complement system is a key component of innate immunity, but impaired regulation influences disease susceptibility, including age-related macular degeneration and some kidney diseases. While complete complement inhibition has been used successfully to treat acute kidney disease, key unresolved challenges include strategies to modulate rather than completely inhibit the system and to deliver therapy potentially over decades. Elevating concentrations of complement factor I (CFI) restricts complement activation in vitro and this approach was extended in the current study to modulate complement activation in vivo. Sustained increases in CFI levels were achieved using an adeno-associated virus (AAV) vector to target the liver, inducing a 4- to 5-fold increase in circulating CFI levels. This led to decreased activity of the alternative pathway as demonstrated by a reduction in the rate of inactive C3b (iC3b) deposition and more rapid formation of C3 degradation products. In addition, vector application in a mouse model of systemic lupus erythematosus (NZBWF1), where tissue injury is, in part, complement dependent, resulted in reduced complement C3 and IgG renal deposition. Collectively, these data demonstrate that sustained elevation of CFI reduces complement activation in vivo providing proof-of-principle support for the therapeutic application of AAV gene delivery to modulate complement activation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice.
- Author
-
Smith-Jackson, Kate, Yi Yang, Denton, Harriet, Pappworth, Isabel Y., Cooke, Katie, Barlow, Paul N., Atkinson, John P., Liszewski, M. Kathryn, Pickering, Matthew C., Kavanagh, David, Cook, H. Terence, Marchbank, Kevin J., and Yang, Yi
- Subjects
- *
THROMBOTIC thrombocytopenic purpura , *COMPLEMENT inhibition , *MOUSE diseases , *GAIN-of-function mutations , *SYNDROMES , *MICE , *KNOCKOUT mice - Abstract
Atypical hemolytic uremic syndrome (aHUS) is frequently associated in humans with loss-of-function mutations in complement-regulating proteins or gain-of-function mutations in complement-activating proteins. Thus, aHUS provides an archetypal complement-mediated disease with which to model new therapeutic strategies and treatments. Herein, we show that, when transferred to mice, an aHUS-associated gain-of-function change (D1115N) to the complement-activation protein C3 results in aHUS. Homozygous C3 p.D1115N (C3KI) mice developed spontaneous chronic thrombotic microangiopathy together with hematuria, thrombocytopenia, elevated creatinine, and evidence of hemolysis. Mice with active disease had reduced plasma C3 with C3 fragment and C9 deposition within the kidney. Therapeutic blockade or genetic deletion of C5, a protein downstream of C3 in the complement cascade, protected homozygous C3KI mice from thrombotic microangiopathy and aHUS. Thus, our data provide in vivo modeling evidence that gain-of-function changes in complement C3 drive aHUS. They also show that long-term C5 deficiency is not accompanied by development of other renal complications (such as C3 glomerulopathy) despite sustained dysregulation of C3. Our results suggest that this preclinical model will allow testing of novel complement inhibitors with the aim of developing precisely targeted therapeutics that could have application in many complement-mediated diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury.
- Author
-
Renner, Brandon, Ferreira, Viviana P., Cortes, Claudio, Goldberg, Ryan, Ljubanovic, Danica, Pangburn, Michael K., Pickering, Matthew C., Tomlinson, Stephen, Holland-Neidermyer, Amanda, Strassheim, Derek, Holers, V. Michael, and Thurman, Joshua M.
- Subjects
- *
GENETIC research , *GENETIC mutation , *KIDNEY diseases , *GENES , *ISCHEMIA - Abstract
Factor H is a regulator of the alternative pathway of complement, and genetic studies have shown that patients with mutations in factor H are at increased risk for several types of renal disease. Pathogenic activation of the alternative pathway in acquired diseases, such as ischemic acute kidney injury, suggests that native factor H has a limited capacity to control the alternative pathway in the kidney. Here we found that an absolute deficiency of factor H produced by gene deletion prevented complement activation on tubulointerstitial cells after ischemia/reperfusion (I/R) injury, likely because alternative pathway proteins were consumed in the fluid phase. In contrast, when fluid-phase regulation by factor H was maintained while the interaction of factor H with cell surfaces was blocked by a recombinant inhibitor protein, complement activation after renal I/R increased. Finally, a recombinant form of factor H, specifically targeted to sites of C3 deposition, reduced complement activation in the tubulointerstitium after ischemic injury. Thus, although factor H does not fully prevent activation of the alternative pathway of complement on ischemic tubules, its interaction with the tubule epithelial cell surface is critical for limiting complement activation and attenuating renal injury after ischemia. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
19. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.
- Author
-
Fakhouri, Fadi, de Jorge, Elena Goicoechea, Brune, Frédérique, Azam, Philippe, Cook, H Terence, and Pickering, Matthew C.
- Subjects
- *
KIDNEY diseases , *LABORATORY mice , *BLOOD plasma , *PROTEINS , *BASAL lamina - Abstract
Total deficiency of complement factor H (CFH) is associated with dense deposit disease and atypical hemolytic uremic syndrome. CFH is the major regulator of the alternative pathway of complement activation and its complete deficiency results in uncontrolled C3 activation through this pathway and secondary C3 deficiency. Plasma infusion, as a source of CFH, has been used with variable success to treat renal disease associated with its deficiency. However, the risks of volume and protein overload limit this therapeutic approach. In this study, we investigated the efficacy of a purified human CFH (hCFH) preparation in Cfh-gene knockout mice. These mice spontaneously develop both secondary plasma C3 deficiency and a renal abnormality characterized by massive accumulation of C3 along the glomerular basement membrane. The renal lesion is analogous to human dense deposit disease. Treatment of knockout mice with hCFH resulted in rapid normalization of plasma C3 levels and resolution of the glomerular basement membrane C3 deposition. Long-term treatment of mice with hCFH was not possible because of the development of an immune response against hCFH. Hence, we suggest that hCFH can be an effective alternative therapy to plasma infusions in patients with renal disease associated with CFH deficiency. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
20. Complement in human diseases: Lessons from complement deficiencies
- Author
-
Botto, Marina, Kirschfink, Michael, Macor, Paolo, Pickering, Matthew C., Würzner, Reinhard, and Tedesco, Francesco
- Subjects
- *
COMPLEMENT deficiency (Immunology) , *IMMUNODEFICIENCY , *IMMUNE complex diseases , *BACTERIAL diseases , *HEALTH surveys , *MOLECULAR biology , *DIAGNOSIS - Abstract
Abstract: Complement deficient cases reported in the second half of the last century have been of great help in defining the role of complement in host defence. Surveys of the deficient individuals have been instrumental in the recognition of the clinical consequences of the deficiencies. This review focuses on the analysis of the diseases associated with the deficiencies of the various components and regulators of the complement system and their therapeutic implications. The diagnostic approach leading to the identification of the deficiency is discussed here as a multistep process that starts with the screening assays and proceeds in specialized laboratories with the characterization of the defect at the molecular level. The organization of a registry of complement deficiencies is presented as a means to collect the cases identified in and outside Europe with the aim to promote joint projects on treatment and prevention of diseases associated with defective complement function. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
21. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury
- Author
-
Ruseva, Marieta M., Hughes, Timothy R., Donev, Rossen M., Sivasankar, Baalasubramanian, Pickering, Matthew C., Wu, Xiaobo, Harris, Claire L., and Morgan, B. Paul
- Subjects
- *
COMPLEMENT (Immunology) , *GENETIC regulation , *IMMUNOGENETICS , *GENETIC mutation , *LABORATORY mice , *KIDNEY injuries , *KIDNEY tubules - Abstract
Abstract: The rodent-specific complement regulator complement receptor 1-related gene/protein-y (Crry) is critical for complement homeostasis. Gene deletion is 100% embryonically lethal; Crry-deficient (Crry−/−) mice were rescued by back-crossing onto C3 deficiency, confirming that embryo loss was complement mediated. In order to rescue viable Crry−/− mice without deleting C3, we have tested inhibition of C5 during gestation. Crry+/− females were given neutralizing anti-C5 mAb immediately prior to mating with Crry+/− males and C5 inhibition maintained through pregnancy. A single, healthy Crry−/− female was obtained and mating with Crry+/− males yielded healthy litters containing equal numbers of Crry+/− and Crry−/− pups. Inter-crossing Crry−/− mice yielded healthy litters of expected size. Although the mice were not anemic, exposure of Crry−/− erythrocytes to normal mouse serum caused C3 deposition and lysis, while transfusion into normal or C6−/− mice resulted in rapid clearance. Complement activity and C3 levels in Crry−/− mice were markedly reduced. Comparison with factor H deficient (CfH−/−) mice revealed similar levels of residual C3; however, unlike the CfH−/− mice, Crry−/− mice showed no evidence of renal injury, demonstrating distinct roles for these regulators in protecting the kidney. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.